Protalix BioTherapeutics Inc.
ASE:PLX 4:00:00 PM EDT
| Market Cap (Intraday) | 117.03M |
| Current PE | 29.95 |
| Forward PE | 10.5 |
| 2yr Forward PE | 3.27 |
| 10-Day MA | $1.48 |
| 50-Day MA | $1.82 |
| 200-Day MA | $1.88 |
Protalix BioTherapeutics Inc. Stock, ASE:PLX
2 University Plaza, Suite 100, Hackensack, New Jersey 07601
United States of America
Phone: +1.201.696.9345
Number of Employees: 213
Description
Protalix Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development, production, and commercialization of recombinant therapeutic proteins based on plant cell based expression system. Its products include Alidornase alfa, PRX-115 and PRX-11. The company was by Yoseph Shaaltiel in 1993 and is headquartered in Hackensack, NJ.